Journal ArticleDOI
Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012
Diane K. Wysowski,Patty Greene +1 more
Reads0
Chats0
TLDR
There has been a substantial decline in prescriptions and sales of oral and intravenous bisphosphonates for osteoporosis treatment in the United States since 2007-2008 and since 2010.About:
This article is published in Bone.The article was published on 2013-12-01. It has received 122 citations till now. The article focuses on the topics: Bisphosphonate.read more
Citations
More filters
Journal ArticleDOI
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
TL;DR: The plateauing and subsequent decline in oral bisphosphonate use since 2006 coincided with reports of safety concerns of bisph phosphonates, despite the fact that U.S. Food and Drug Administration and ASBMR reports did not recommend any safety restrictions on their use.
Journal ArticleDOI
Hip fracture trends in the United States, 2002 to 2015.
E. Michael Lewiecki,Nicole C. Wright,Jeffrey R. Curtis,Ethel S. Siris,Robert F. Gagel,Kenneth G. Saag,Andrea Singer,P. M. Steven,Robert A. Adler,Robert A. Adler +9 more
TL;DR: An analysis of United States Medicare claims data from 2002 to 2015 for women aged ≥ 65 years found that age-adjusted hip fracture rates for 2013, 2014, and 2015 were higher than projected, resulting in an estimated increase of more than 11,000 hip fractures.
Journal ArticleDOI
Targeted delivery to bone and mineral deposits using bisphosphonate ligands.
TL;DR: This article summarizes the current state of knowledge and practice for the use of BPs as ligands for targeted delivery to bone and mineral deposits and introduces Mechanisms of binding and the relative binding affinity of various BPs to bone mineral.
Journal ArticleDOI
Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
John A. Kanis,John A. Kanis,Cyrus Cooper,René Rizzoli,Bo Abrahamsen,Nasser M. Al-Daghri,M. L. Brandi,Jorge B. Cannata-Andía,Bernard Cortet,H. P. Dimai,Serge Ferrari,Peyman Hadji,Nicholas C. Harvey,Marius E. Kraenzlin,Andreas Kurth,Eugene V. McCloskey,Salvatore Minisola,Theda Thomas,Jean-Yves Reginster +18 more
TL;DR: There is a significant treatment gap between those who would benefit from treatment and those who receive it, which urgently needs to be addressed so that the burden of disease can be reduced.
References
More filters
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black,Pierre D. Delmas,Richard Eastell,Ian R. Reid,Steven Boonen,Jane A. Cauley,Felicia Cosman,Peter L. Lakatos,Ping Chung Leung,Z. Man,Carlos Mautalen,Peter Mesenbrink,Huilin Hu,John Caminis,Karen Tong,Theresa Rosario-Jansen,Joel S. Krasnow,Trisha F. Hue,Deborah E. Sellmeyer,Erik Fink Eriksen,Steven R. Cummings +20 more
TL;DR: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo.
Journal ArticleDOI
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
Steven R. Cummings,Dennis M. Black,Desmond E. Thompson,William B. Applegate,Elizabeth Barrett-Connor,Thomas Musliner,Lisa Palermo,Ronald J. Prineas,Susan M. Rubin,Jean Scott,Thomas M. Vogt,Robert B. Wallace,A. John Yates,Andrea Z. LaCroix +13 more
TL;DR: In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity.
Journal ArticleDOI
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Uri A. Liberman,Stuart R. Weiss,Johann Broll,Helmut W. Minne,Hui Quan,Norman H. Bell,Jose Adolfo Rodriguez-Portales,Robert W. Downs,Jan Dequeker,Murray J. Favus,Ego Seeman,Robert R. Recker,Thomas P. Capizzi,Arthur C. Santora,Antonio Lombardi,Raksha V. Shah,Laurence J. Hirsch,David B. Karpf +17 more
TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.
Journal ArticleDOI
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
TL;DR: In view of the current trend of increasing and widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized potential complication.
Related Papers (5)
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Elizabeth Shane,David B. Burr,Peter R. Ebeling,Bo Abrahamsen,Robert A. Adler,Thomas D. Brown,Angela M. Cheung,Felicia Cosman,Jeffrey R. Curtis,Richard M. Dell,David W. Dempster,Thomas A. Einhorn,Harry K. Genant,Piet Geusens,Klaus Klaushofer,Kenneth J. Koval,Joseph M. Lane,Fergus McKiernan,Ross E. McKinney,Alvin Choong Meng Ng,Jeri W. Nieves,Regis J. O'Keefe,Socrates E. Papapoulos,Howe Tet Sen,Marjolein C. H. van der Meulen,Robert S. Weinstein,Michael P. Whyte +26 more
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black,Pierre D. Delmas,Richard Eastell,Ian R. Reid,Steven Boonen,Jane A. Cauley,Felicia Cosman,Peter L. Lakatos,Ping Chung Leung,Z. Man,Carlos Mautalen,Peter Mesenbrink,Huilin Hu,John Caminis,Karen Tong,Theresa Rosario-Jansen,Joel S. Krasnow,Trisha F. Hue,Deborah E. Sellmeyer,Erik Fink Eriksen,Steven R. Cummings +20 more